Recent patent disclosures illustrate how modern medicinal chemistry advances by aligning biological insight with chemical modality, formulation rigor, and molecular measurement. Targeted protein degradation to overcome resistance, solid-state engineering to ensure sustained pathway suppression, and single-cell genomic profiling to resolve metastatic biology together demonstrate how therapeutic impact emerges when perturbation, delivery, and biological observability are coherently integrated.
Renner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: